Adult Dosing

Skin and skin structure infections

• 2-dose regimen of 1,000 mg IV followed 1 week later by 500 mg IV
• Infuse IV over 30 minutes

Note:

• Refer package insert for preparation and administration procedure

Pediatric Dosing

• Safety and efficacy have not been established in pediatric patients

• Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive bacteria

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment (Based on CrCl)

• 30 mL/min: Decrease dose to 750 mg IV followed 1 week later by 375 mg IV
• Regularly scheduled hemodialysis: No dose adjustments

Hepatic Dose Adjustment

• Mild impairment: No dose adjustments
• Moderate or severe hepatic impairment: Use with caution

• Serious hypersensitivity reactions, including anaphylactic reactions, some of which may be fatal has been reported following first or subsequent doses of dalbavancin. Discontinue therapy at first signs of hypersensitivity
• Use dalbavancin cautiously in patients with a history of glycopeptide allergy
• Rapid IV infusion can cause "red man syndrome"–like reactions; administer over 30 mins to reduce risk of infusion related reactions (flushing of the upper body, urticaria, pruritus, or rash)
• Clostridium difficile-associated diarrhea (CDAD), ranging in severity from mild diarrhea to fatal colitis has been reported; consider CDAD in patients with diarrhea following antibiotic use
• To reduce the development of drug-resistant bacteria and maintain the effectiveness, administer dalbavancin only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria

Pregnancy Category:C

Breastfeeding: Safety unknown; manufacturer advises caution.

• CNS: Headache, dizziness
• GI: Nausea, vomiting, diarrhea, gastrointestinal hemorrhage, melena, hematochezia, abdominal pain, clostridium difficile colitis, oral candidiasis
• GU: Vulvovaginal mycotic infection
• HEMA: Anemia, hemorrhagic anemia, leucopenia, neutropenia, thrombocytopenia, petechiae, eosinophilia, thrombocytosis
• HEPA: Hepatotoxicity
• METABOLIC: Hypoglycemia
• DERM: Rash, pruritus, urticaria
• RESP: Bronchospasm
• LABTEST: Hepatic transaminases increased, blood alkaline phosphatase increased, international normalized ratio increased
• LOCAL: Infusion-related reactions
• HYPERSENSITIVITY: Anaphylactoid reaction

• Antibacterial; inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptidoglycan; binds to bacterial membrane and disrupts membrane barrier function
• Metabolism: Unknown
• Excreted in urine ( 33%); (12%) metabolite in urine; and (20%)in feces
• Half-life: 346 hours

US Trade Name(s)

• Dalvance

US Availability

Dalvance

• INJ: 500 mg/vial (lyophilized powder)

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Antimicrobials

Antibiotics

Glycopeptides

Infectious Disease

Antibiotics

Glycopeptides